(2026). Robust response to pembrolizumab in temozolomide-associated hypermutated and microsatellite instability-high functional pancreatic neuroendocrine tumor. The Oncologist.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Robust Response to Pembrolizumab in Temozolomide-associated Hypermutated and Microsatellite Instability-high Functional Pancreatic Neuroendocrine Tumor."
The Oncologist 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Robust Response to Pembrolizumab in Temozolomide-associated Hypermutated and Microsatellite Instability-high Functional Pancreatic Neuroendocrine Tumor."
The Oncologist, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.